SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+32.15%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$901M
AUM Growth
+$901M
(-9.2%)
Cap. Flow
-$248M
Cap. Flow
% of AUM
-27.47%
Top 10 Holdings %
Top 10 Hldgs %
45.07%
Holding
107
New
16
Increased
16
Reduced
34
Closed
33
Top Buys
| 1 |
HCA Healthcare
HCA
|
$27.5M |
| 2 |
IDEAYA Biosciences
IDYA
|
$20.1M |
| 3 |
Penumbra
PEN
|
$20M |
| 4 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$18.4M |
| 5 |
GSK
GSK
|
$12.4M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$38.2M |
| 2 |
Arcellx
ACLX
|
$26.9M |
| 3 |
Insulet
PODD
|
$20.4M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$20.3M |
| 5 |
Evolus
EOLS
|
$19M |
Sector Composition
| 1 | Healthcare | 99.95% |
| 2 | Consumer Staples | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Syndax Pharmaceuticals
SNDX
$1.39B
| $11.1M | 1.23% |
514,000
+394,500
| +330% | +$8.53M |
|
|
27
TG Therapeutics
TGTX
$5.03B
| $11.1M | 1.23% |
650,000
-2,234,382
| -77% | -$38.2M |
|
28
C4 Therapeutics
CCCC
$182M
| $10.4M | 1.15% |
1,835,996
-856,024
| -32% | -$4.84M |
|
29
BioAtla
BCAB
$28.7M
| $10M | 1.11% |
4,065,197
-291,000
| -7% | -$716K |
|
30
Transmedics
TMDX
$3.65B
| $9.72M | 1.08% |
+123,112
| New | +$9.72M |
|
|
HARP
31
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $9.33M | 1.04% |
+820,638
| New | +$9.33M |
|
|
32
Arcellx
ACLX
$3.95B
| $8.82M | 0.98% |
159,000
-484,777
| -75% | -$26.9M |
|
|
CMPS
33
Compass Pathways
CMPS
$452M
| $8.44M | 0.94% |
964,550
| – | – |
|
34
Tango Therapeutics
TNGX
$745M
| $8.39M | 0.93% |
847,145
-1,081,874
| -56% | -$10.7M |
|
35
Merus
MRUS
$5.04B
| $8.32M | 0.92% |
302,577
-81,913
| -21% | -$2.25M |
|
36
Viking Therapeutics
VKTX
$3.02B
| $8.12M | 0.9% |
436,200
+314,000
| +257% | +$5.84M |
|
37
Jasper Therapeutics
JSPR
$44.2M
| $7.79M | 0.86% |
9,870,980
+1,570,000
| +19% | +$1.24M |
|
|
THTX
38
Theratechnologies
THTX
$149M
| $7.78M | 0.86% |
4,801,376
+2,470,000
| +106% | +$4M |
|
39
Revolution Medicines
RVMD
$7.43B
| $7.23M | 0.8% |
+252,000
| New | +$7.23M |
|
40
SI-BONE Inc
SIBN
$700M
| $7.17M | 0.8% |
341,818
-300,471
| -47% | -$6.31M |
|
|
SILK
41
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $6.59M | 0.73% |
+537,000
| New | +$6.59M |
|
42
Pharvaris
PHVS
$1.41B
| $6.1M | 0.68% |
217,396
-126,579
| -37% | -$3.55M |
|
43
Insmed
INSM
$30.3B
| $5.18M | 0.57% |
167,100
-50,900
| -23% | -$1.58M |
|
44
Krystal Biotech
KRYS
$4.35B
| $4.96M | 0.55% |
40,000
-77,892
| -66% | -$9.66M |
|
45
CVS Health
CVS
$93B
| $4.7M | 0.52% |
59,500
-133,054
| -69% | -$10.5M |
|
46
Iovance Biotherapeutics
IOVA
$800M
| $4.51M | 0.5% |
555,000
-684,777
| -55% | -$5.57M |
|
47
NovoCure
NVCR
$1.35B
| $4.49M | 0.5% |
301,000
-43,100
| -13% | -$643K |
|
48
InspireMD
NSPR
$101M
| $3.87M | 0.43% |
1,378,128
| – | – |
|
49
Viridian Therapeutics
VRDN
$1.59B
| $3.01M | 0.33% |
+138,000
| New | +$3.01M |
|
50
Denali Therapeutics
DNLI
$2.24B
| $2.79M | 0.31% |
+130,000
| New | +$2.79M |
|